MindBio Therapeutics (XCNQ:MBIO) Debt-to-EBITDA : 7.31 (As of Mar. 2024)

View and export this data going back to 2023. Start your Free Trial

What is MindBio Therapeutics Debt-to-EBITDA?

Debt-to-EBITDA measures a company's ability to pay off its debt.

MindBio Therapeutics's Short-Term Debt & Capital Lease Obligation for the quarter that ended in Mar. 2024 was C$0.96 Mil. MindBio Therapeutics's Long-Term Debt & Capital Lease Obligation for the quarter that ended in Mar. 2024 was C$3.55 Mil. MindBio Therapeutics's annualized EBITDA for the quarter that ended in Mar. 2024 was C$0.62 Mil. MindBio Therapeutics's annualized Debt-to-EBITDA for the quarter that ended in Mar. 2024 was 7.31.

A high Debt-to-EBITDA ratio generally means that a company may spend more time to paying off its debt. According to Joel Tillinghast's BIG MONEY THINKS SMALL: Biases, Blind Spots, and Smarter Investing, a ratio of Debt-to-EBITDA exceeding four is usually considered scary unless tangible assets cover the debt.

The historical rank and industry rank for MindBio Therapeutics's Debt-to-EBITDA or its related term are showing as below:

XCNQ:MBIO' s Debt-to-EBITDA Range Over the Past 10 Years
Min: -1.67 Med: -0.96 Max: -0.62
Current: -1.67

During the past 3 years, the highest Debt-to-EBITDA Ratio of MindBio Therapeutics was -0.62. The lowest was -1.67. And the median was -0.96.

XCNQ:MBIO's Debt-to-EBITDA is ranked worse than
100% of 270 companies
in the Biotechnology industry
Industry Median: 1.31 vs XCNQ:MBIO: -1.67

MindBio Therapeutics Debt-to-EBITDA Historical Data

The historical data trend for MindBio Therapeutics's Debt-to-EBITDA can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

MindBio Therapeutics Debt-to-EBITDA Chart

MindBio Therapeutics Annual Data

Trend

Jun21

Jun22

Jun23

Debt-to-EBITDA

N/A

-0.62

-1.30

MindBio Therapeutics Quarterly Data
	Dec21	Mar22	Jun22	Sep22	Dec22	Mar23	Jun23	Sep23	Dec23	Mar24
Debt-to-EBITDA	Get a 7-Day Free Trial					-5.49	-0.39	-9.39	14.22	7.31

Competitive Comparison of MindBio Therapeutics's Debt-to-EBITDA

For the Biotechnology subindustry, MindBio Therapeutics's Debt-to-EBITDA, along with its competitors' market caps and Debt-to-EBITDA data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.

MindBio Therapeutics's Debt-to-EBITDA Distribution in the Biotechnology Industry

For the Biotechnology industry and Healthcare sector, MindBio Therapeutics's Debt-to-EBITDA distribution charts can be found below:

* The bar in red indicates where MindBio Therapeutics's Debt-to-EBITDA falls into.

MindBio Therapeutics Debt-to-EBITDA Calculation

Debt-to-EBITDA measures a company's ability to pay off its debt.

MindBio Therapeutics's Debt-to-EBITDA for the fiscal year that ended in Jun. 2023 is calculated as

Debt-to-EBITDA	=	Total Debt			/	EBITDA
	=	(Short-Term Debt & Capital Lease Obligation	+	Long-Term Debt & Capital Lease Obligation)	/	EBITDA
	=	(1.922	+	2.512)	/	-3.42
	=	-1.30

MindBio Therapeutics's annualized Debt-to-EBITDA for the quarter that ended in Mar. 2024 is calculated as

Debt-to-EBITDA	=	Total Debt			/	EBITDA
	=	(Short-Term Debt & Capital Lease Obligation	+	Long-Term Debt & Capital Lease Obligation)	/	EBITDA
	=	(0.955	+	3.545)	/	0.616
	=	7.31

In the calculation of annual Debt-to-EBITDA, the EBITDA of the last fiscal year is used. In calculating the annualized quarterly data, the EBITDA data used here is four times the quarterly (Mar. 2024) EBITDA data.

MindBio Therapeutics (XCNQ:MBIO) Debt-to-EBITDA Explanation

In the calculation of Debt-to-EBITDA, we use the total of Short-Term Debt & Capital Lease Obligation and Long-Term Debt & Capital Lease Obligation divided by EBITDA. In some calculations, Total Liabilities is used to for calculation.

Be Aware

A high Debt-to-EBITDA ratio generally means that a company may spend more time to paying off its debt.

According to Joel Tillinghast's BIG MONEY THINKS SMALL: Biases, Blind Spots, and Smarter Investing, a ratio of Debt-to-EBITDA exceeding four is usually considered scary unless tangible assets cover the debt.

MindBio Therapeutics Debt-to-EBITDA Related Terms

Thank you for viewing the detailed overview of MindBio Therapeutics's Debt-to-EBITDA provided by GuruFocus.com. Please click on the following links to see related term pages.

MindBio Therapeutics (XCNQ:MBIO) Business Description

Industry

GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » MindBio Therapeutics Corp (XCNQ:MBIO) » Definitions » Debt-to-EBITDA

Comparable Companies

Traded in Other Exchanges

WF6:Germany

Address

91-97 William Street, Level 4, Melbourne, VIC, AUS, 3000

Website

https://www.mindbiotherapeutics.com

MindBio Therapeutics Corp is pioneering clinical studies into the microdosing of psychedelic medicines to treat a range of medical conditions such as depression, anxiety, PTSD, panic disorder, chronic pain and opiate addictions. Its clinical trials microdosing of psychedelic medicines provide hope for sufferers of mental health conditions with new emerging treatment alternatives. The company invests in clinical research to discover potential new treatment options and aims to create novel medicines and treatment regimes from breakthrough microdosing studies. Geographically, the activities of the company takes place in Australia.